High Usability and Applicability Ratings for the New SmartClic®/ClicWise® Injection Device: Evidence from a Health Care Professional Opinion Study

Rieke Alten; Simon Moss; Stefanie Hahne; Angela T Muriset; David Gruben; Mark Latymer

doi:10.1007/s40744-022-00520-2

High Usability and Applicability Ratings for the New SmartClic^®/ClicWise^® Injection Device: Evidence from a Health Care Professional Opinion Study

Rheumatol Ther. 2023 Apr;10(2):477-487. doi: 10.1007/s40744-022-00520-2. Epub 2023 Jan 22.

Authors

Rieke Alten¹, Simon Moss², Stefanie Hahne³, Angela T Muriset⁴, David Gruben⁵, Mark Latymer⁶

Affiliations

¹ Department of Internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany.
² Pfizer, Cambridge, UK.
³ Pfizer, Berlin, Germany.
⁴ Design Science, Evanston, IL, USA.
⁵ Pfizer, Groton, CT, USA.
⁶ Inflammation and Immunology Global Medical Affairs, Pfizer Biopharmaceuticals Group, Ramsgate Road, Sandwich, CT13 9NJ, UK. mark.latymer@pfizer.com.

Abstract

Introduction: The SmartClic^®/ClicWise^® autoinjector is a new reusable, multi-use, single-patient device for the administration of subcutaneously administered biologics in the treatment of chronic conditions, including rheumatoid arthritis. The device will be used in conjunction with a mobile application (app). The aim of this study was to collect feedback on the usability, functionality, and applicability of the device and the companion app from health care professionals (HCPs) who perform injections as part of their role and care for patients with rheumatic conditions.

Methods: The study was conducted from September to October 2020 in Germany. HCPs participated in a training session for the device and gained experience by performing simulated injections with water. Following the simulations, HCPs answered questions on the ease of use, feature design, effectiveness, and injection speed of the SmartClic/ClicWise device and estimate the patient training time required. They also answered questions on the functionality of the proposed app after attending a storyboard presentation. Responses were recorded as multiple-choice answers, Likert scale ratings (seven-point scale), or open-ended comments. The mean, median, and mode scores were recorded.

Results: Twenty-five HCPs (mean age, 38.2 years; females, n = 22 [88%]; registered nurses, n = 19 [76%]) participated in the study. HCP feedback on questions related to the SmartClic/ClicWise device was positive overall, with mean scores > 4.50 across questions; mean scores < 5.00 were reported on 2/40 questions. Twenty-four of 25 participants (96%) estimated that a training time of ≤ 20 min would suffice for patients learning to use the device. Positive feedback was also reported on questions related to the companion app, with mean scores > 5.70.

Conclusions: Initial feedback from HCPs on the SmartClic/ClicWise device and proposed app was generally favorable, suggesting they will provide an acceptable alternative for self-administration of biologics for patients with rheumatoid arthritis and other chronic conditions.

Keywords: Autoinjector; Biologics; ClicWise; Human factors; Mobile application; Rheumatoid arthritis; SmartClic; Usability.